As part of the International Liver Congress (ILC) 2021, the EASL Takeaways take a look at key topics from the congress, with leading experts discussing the most impactful science and putting it into perspective. In this episode, join Professor Josep Llovet, Professor Maria Reig, and Professor Helen Reeves as they review key abstracts from ILC 2021 on the topic of liver tumours.
Professor Llovet starts the session with four abstracts that explored candidate biomarkers associated with treatment outcomes to immunotherapy, before the experts discuss the clinical implications of these biomarkers in more detail. They also examine some of the concerns raised about sub-optimal responses to immunotherapy observed in non-viral compared to viral HCC patients, particularly NAFLD HCC patients. Professor Reig then takes the experts through some of the clinical trials in immunotherapy that were presented at the congress, specifically on neoadjuvant nivolumab, pembrolizumab and atezolizumab + bevacizumab.